Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 15,000 shares of Equillium stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $1.25, for a total transaction of $18,750.00. Following the completion of the transaction, the chief operating officer now directly owns 135,246 shares in the company, valued at approximately $169,057.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Equillium Price Performance
Shares of EQ stock opened at $1.38 on Thursday. The stock's fifty day moving average price is $0.97 and its 200 day moving average price is $1.05. Equillium, Inc. has a 1-year low of $0.45 and a 1-year high of $3.25. The company has a market cap of $48.89 million, a price-to-earnings ratio of -5.52 and a beta of 1.83.
Equillium (NASDAQ:EQ - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.16. Equillium had a negative return on equity of 36.88% and a negative net margin of 19.51%. The business had revenue of $13.85 million for the quarter, compared to analyst estimates of $8.15 million. As a group, equities research analysts anticipate that Equillium, Inc. will post -0.14 earnings per share for the current year.
Institutional Trading of Equillium
Countdown to the biggest trade of my 25 yr career
From Timothy Sykes | Ad
Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview…
Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.
Click here to see the surprising reason why
An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC grew its position in Equillium, Inc. (NASDAQ:EQ - Free Report) by 43.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 300,400 shares of the company's stock after purchasing an additional 91,200 shares during the period. Renaissance Technologies LLC owned approximately 0.85% of Equillium worth $208,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.05% of the company's stock.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and issued a $5.00 target price on shares of Equillium in a research note on Monday, August 19th.
Get Our Latest Report on Equillium
Equillium Company Profile
(
Get Free Report)
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
